Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atazanavir isotopic analog
- Development stage
- Phase 1
- Lead developer
- Concert Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
C-10276 is an isotopic analog of atazanavir, a well-known HIV protease inhibitor. It has been investigated as a potential antiretroviral agent and reached Phase 1 clinical trials. The drug was developed by Concert Pharmaceuticals. As an analog of atazanavir, its mechanism of action is presumed to be inhibition of the HIV protease enzyme, thereby preventing viral replication.
- Other names
- C-10276C10276C 10276
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on atazanavir isotopic analog.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atazanavir isotopic analog.